Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 4:47 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 937–960 of 1,038 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Negative Control Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Skin Irritation Potential of MOB015B in Healthy Subjects Using a Cumulative Irritant Patch Test Design

NCT06369675
View directory record Official record
Conditions
Erythema
Interventions
MOB015B, 0.2% SLS, 0.9% Saline, MOB015B vehicle
Drug
Lead sponsor
Moberg Pharma AB
Industry
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Fair Lawn, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 17, 2024 · Synced Oct 21, 2026, 4:47 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Evaluation of a Experimental Denture Adhesive to Prevent Food Ingress

NCT02928380
View directory record Official record
Conditions
Denture Retention
Interventions
Experimental Denture Adhesive, Reference (Marketed) Denture Adhesive
Device
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 85 Years
Enrollment
83 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Fort Wayne, Indiana
Source: ClinicalTrials.gov public record
Updated Aug 27, 2018 · Synced Oct 21, 2026, 4:47 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Reducing Eco-anxiety Using Selfies

NCT05372705
View directory record Official record
Conditions
Ecology, Anxiety
Interventions
Short videos
Behavioral
Lead sponsor
Yale University
Other
Eligibility
14 Years to 18 Years
Enrollment
1,200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
2
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 12, 2022 · Synced Oct 21, 2026, 4:47 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Purpose of This Research Study is to Compare the Effectiveness of a Non-fluoride Whitening Toothpaste (Test) to That of a Non-whitening Fluoride Toothpaste (Negative Control) in Improving Tooth Whiteness (Removal of Extrinsic Stains) Over 8 Weeks of Unsupervised Use.

NCT07219342
View directory record Official record
Conditions
Teeth Staining
Interventions
Toothpaste
Other
Lead sponsor
Boka LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
109 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Fort Wayne, Indiana
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Oct 21, 2026, 4:47 AM EDT
Terminated No phase listed Observational

Comparing Immune Responses to Topical Imiquimod

NCT04809662
View directory record Official record
Conditions
Actinic Keratoses
Interventions
Imiquimod
Drug
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years to 85 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Nov 7, 2024 · Synced Oct 21, 2026, 4:47 AM EDT
Terminated No phase listed Observational

Blood Samples From Patients on a Clinical Trial to CINV During HSCT

NCT00900068
View directory record Official record
Conditions
Breast Cancer, Chronic Myeloproliferative Disorders, Gestational Trophoblastic Tumor, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Nausea and Vomiting, Neuroblastoma, Ovarian Cancer, Testicular Germ Cell Tumor
Interventions
immunoenzyme technique, laboratory biomarker analysis, medical chart review
Other
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years to 120 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated May 9, 2017 · Synced Oct 21, 2026, 4:47 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers Results available

Assessment of Delayed-type Hypersensitivity Reactions to SARS-CoV-2 Peptide Antigens

NCT05216510
View directory record Official record
Conditions
Detection of Delayed-type Hypersensitivity Reactions to SARS-CoV-2 in Individuals Exposed to SARS-CoV-2
Interventions
TNX-2110, TNX-2120, TNX-2130, CANDIN, Diluent
Biological
Lead sponsor
Tonix Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Berlin, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 6, 2024 · Synced Oct 21, 2026, 4:47 AM EDT
Completed Not applicable Interventional

Attention Bias Modification Training for Social Phobia (ABMSP)

NCT06054386
View directory record Official record
Conditions
Social Anxiety Disorder
Interventions
Attentional Bias Modification Training (ABMT), General Attention Control Training
Other
Lead sponsor
University of Wisconsin, Milwaukee
Other
Eligibility
18 Years to 60 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Oct 21, 2026, 4:47 AM EDT
Withdrawn Phase 1Phase 2 Interventional

C-Met Inhibitor AMG 337, Oxaliplatin, Leucovorin Calcium, and Fluorouracil in Treating Patients With Advanced Stomach or Esophageal Cancer

NCT02344810
View directory record Official record
Conditions
Adenocarcinoma of the Esophagus, Adenocarcinoma of the Gastroesophageal Junction, Diffuse Adenocarcinoma of the Stomach, Gastrointestinal Cancer, Intestinal Adenocarcinoma of the Stomach, Mixed Adenocarcinoma of the Stomach, Stage IIIA Esophageal Cancer, Stage IIIA Gastric Cancer, Stage IIIB Esophageal Cancer, Stage IIIB Gastric Cancer, Stage IIIC Esophageal Cancer, Stage IIIC Gastric Cancer, Stage IV Esophageal Cancer, Stage IV Gastric Cancer
Interventions
c-Met inhibitor AMG 337, placebo, oxaliplatin, leucovorin calcium, fluorouracil, pharmacological study, laboratory biomarker analysis
Drug · Other
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2015
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 25, 2023 · Synced Oct 21, 2026, 4:47 AM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Vitamin D Supplementation in HIV Youth

NCT01523496
View directory record Official record
Conditions
HIV Infections
Interventions
Vitamin D control dose, Vitamin D supplementation-
Drug
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
8 Years to 25 Years
Enrollment
190 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2016
U.S. locations
2
States / cities
Atlanta, Georgia • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 8, 2018 · Synced Oct 21, 2026, 4:47 AM EDT
Completed Not applicable Interventional

Assessing the Utility of Cognitive Behavioral Therapy for Pain Control in Patients With Chronic Pancreatitis

NCT03112759
View directory record Official record
Conditions
Chronic Pancreatitis
Interventions
Cognitive Behavioral Therapy
Behavioral
Lead sponsor
University of Louisville
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Jun 18, 2021 · Synced Oct 21, 2026, 4:47 AM EDT
Active, not recruiting Phase 2 Interventional

Artesunate Suppositories for the Treatment of HIV-negative Patients With Intra-anal HSIL

NCT05555862
View directory record Official record
Conditions
Anal High Grade Squamous Intraepithelial Lesion, Anal Precancerous Condition, AIN 2/3, HPV Infection, Anal Dysplasia, HPV Disease
Interventions
Artesunate, Placebo
Drug
Lead sponsor
Frantz Viral Therapeutics, LLC
Industry
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
2
States / cities
Chicago, Illinois • New York, New York
Source: ClinicalTrials.gov public record
Updated May 18, 2025 · Synced Oct 21, 2026, 4:47 AM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate the Efficacy of ASP1128 (MA-0217) in Subjects at Risk for Acute Kidney Injury (AKI) Following Coronary Artery Bypass Graft (CABG) and/or Valve Surgery

NCT03941483
View directory record Official record
Conditions
Acute Kidney Injury (AKI)
Interventions
ASP1128, Placebo
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
35 Years and older
Enrollment
351 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
27
States / cities
Huntsville, Alabama • Tucson, Arizona • Clearwater, Florida + 23 more
Source: ClinicalTrials.gov public record
Updated Dec 4, 2024 · Synced Oct 21, 2026, 4:47 AM EDT
Completed Phase 3 Interventional Results available

A Study of Atezolizumab in Combination With Nab-Paclitaxel Compared With Placebo With Nab-Paclitaxel for Participants With Previously Untreated Metastatic Triple-Negative Breast Cancer (IMpassion130)

NCT02425891
View directory record Official record
Conditions
Triple Negative Breast Cancer
Interventions
Atezolizumab (MPDL3280A), an engineered anti-PDL1 antibody, Nab-Paclitaxel, Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
902 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
49
States / cities
Birmingham, Alabama • Springdale, Arkansas • Oakland, California + 42 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2022 · Synced Oct 21, 2026, 4:47 AM EDT
Recruiting Phase 4 Interventional

Combined OFM and Vacuum-assisted Therapy for Expedited Regeneration Over Structures

NCT07385313
View directory record Official record
Conditions
Soft Tissue Defects, Soft Tissue Wounds, Traumatic Soft Tissue Defect
Interventions
Myriad™ applied in conjunction with NPWT, NPWT Alone
Device
Lead sponsor
Aroa Biosurgery Limited
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
2
States / cities
Aurora, Colorado • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Oct 21, 2026, 4:47 AM EDT
Recruiting Phase 3 Interventional

Antibiotic Cement Bead Pouch Versus Negative Pressure Wound Therapy

NCT05615844
View directory record Official record
Conditions
Open tíbia Fracture
Interventions
Antibiotic Cement Bead Pouch, Negative Pressure Wound Therapy
Drug · Device
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older
Enrollment
312 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
30
States / cities
Chandler, Arizona • Tucson, Arizona • Davis, California + 25 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 21, 2026, 4:47 AM EDT
Completed No phase listed Observational

Long-Term Sequelae of SARS-COV-2 Infection: Diabetes Mellitus

NCT05867017
View directory record Official record
Conditions
COVID-19, Diabete Mellitus
Interventions
Measure of physiologic parameters
Other
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years to 75 Years
Enrollment
23 participants
Timeline
2023 – 2025
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jan 7, 2026 · Synced Oct 21, 2026, 4:47 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

A Study to Investigate a Method to Measure Food Occlusion by Denture Adhesives in Denture Wearers

NCT03345108
View directory record Official record
Conditions
Denture Retention
Interventions
Denture Adhesive Cream (Conventional Application), Denture Adhesive (Continuous Strip Application), No Adhesive
Device · Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 85 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Fort Wayne, Indiana
Source: ClinicalTrials.gov public record
Updated Mar 29, 2019 · Synced Oct 21, 2026, 4:47 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Antibiotic Loaded Cement After TKA

NCT05429671
View directory record Official record
Conditions
Total Knee Arthoplasty
Interventions
total knee arthroplasty, Tobramycin, Gentamicin, Antibiotic cement spacer
Procedure · Drug · Device
Lead sponsor
Rothman Institute Orthopaedics
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 30, 2024 · Synced Oct 21, 2026, 4:47 AM EDT
Recruiting Early Phase 1 Interventional

Micro/Nanobubbles (MNBs) for Treatment of Acute and Chronic Wounds

NCT05169814
View directory record Official record
Conditions
Open Wound, Wound Heal
Interventions
Micro/nanobubble (MNB) - Irrigation, 0.9% Normal Saline - Irrigation, Micro/nanobubble (MNB) - Negative Pressure Wound Therapy with Instillation (NPWTi), 0.9% Normal Saline - Negative Pressure Wound Therapy with Instillation (NPWTi)
Drug · Other
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Oct 2, 2025 · Synced Oct 21, 2026, 4:47 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

In Situ Comparison of the Remineralization Potential of Optimized Fluoride Dentifrice With Control Fluoride Dentifrice

NCT06010732
View directory record Official record
Conditions
Caries
Interventions
0 ppm F (placebo, negative control), 1100 ppm F as sodium fluoride (positive control), 1100 ppm F as sodium fluoride Test Product
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 85 Years
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jun 15, 2025 · Synced Oct 21, 2026, 4:47 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Application of Plasma Circulating HPV DNA Testing to Management of Cervical Intraepithelial Neoplasia

NCT04274465
View directory record Official record
Conditions
Cervix Lesion, Cervical Cancer
Interventions
digital PCR (dPCR) assay
Diagnostic Test
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years to 99 Years · Female only
Enrollment
145 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2024
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 14, 2024 · Synced Oct 21, 2026, 4:47 AM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate Efficacy and Safety of Roluperidone (MIN-101) in Adult Patients With Negative Symptoms of Schizophrenia

NCT03397134
View directory record Official record
Conditions
Negative Symptoms of Schizophrenia
Interventions
Placebo Oral Tablet, Roluperidone 32 mg, Roluperidone 64 mg
Drug
Lead sponsor
Minerva Neurosciences
Industry
Eligibility
18 Years to 55 Years
Enrollment
515 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
13
States / cities
Rogers, Arkansas • Culver City, California • Garden Grove, California + 10 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2023 · Synced Oct 21, 2026, 4:47 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

A Pilot Study for Toxicity Evaluation of HIV Rectal Microbicides

NCT00389311
View directory record Official record
Conditions
HIV Infections
Interventions
Normosol-R, Nonoxynol-9, Gastrointestinal instrumentation
Drug · Procedure
Lead sponsor
Johns Hopkins University
Other
Eligibility
21 Years and older · Male only
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 1, 2015 · Synced Oct 21, 2026, 4:47 AM EDT